BioLineRx (BLRX) Tops Q3 EPS by 4c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/23/2026

1. RNG
2. WDC
3. DECK
4. BYD
5. WCN
6. SPOT
7. FIX
8. BE
9. BMY
10. PNFP

Go back to BioLineRx (BLRX) Tops Q3 EPS by 4c

BioLineRx Reports Third Quarter 2016 Financial Results

November 22, 2016 8:00 AM EST

TEL AVIV, Israel, Nov. 22, 2016 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX; TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, today reports its financial results for the third quarter ended September 30, 2016.

Highlights and achievements during third quarter of 2016 and to date:

Signing of significant immuno-oncology collaboration with Genentech, a member of the Roche Group, for several Phase 1b studies for BL-8040 in combination with Genentech's Atezolizumab, in multiple solid tumor indications and AML Steady progress... More